Enfortumab vedotin (urothelial cancer (UC), pretreated with platinum-containing chemotherapy and PD-(L)-1 inhibitor)


  • Active Substance: Enfortumab vedotin
  • Name: Padcev®
  • Therapeutic area: Urothelial cancer (UC)
  • Pharmaceutical company: Astellas Pharma Europe B.V.

Time table:

  • Start: 01.06.2022
  • Final decision by G-BA: 01.12.2022

Final decision:

  1. Patients who are eligible for a chemotherapy: Hint for a considerable additional benefit
  2. Patients who are not eligible for a chemotherapy: No additional benefit proved